CEL-SCI Corporation, Teva Pharmaceuticals Expand Licensing Agreement

CEL-SCI announced it has expanded the licensing agreement with Teva Pharmaceutical for its cancer drug Multikine. Under the agreement, Teva’s exclusive license to market and distribute Multikine will be extended to include Croatia and Serbia.
The Street